• Xiaoyu Zhang, Yong Wang, Qiang Guo, Yutao Diao, Hongyan Liu, Guanhua Song, Wei Wang, Zhiyong Zhang, Haipeng Yin, and Lianlian Li.
• Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China.
• Clin. Chim. Acta. 2018 Aug 1; 483: 6-13.

BackgroundRecent studies have shown that microRNA-155 (miR-155) is correlated with clinical outcomes of leukemia. This meta-analysis explores to evaluate the prognostic value of miR-155 for survival in patients with leukemia.MethodsEligible studies were searched from PubMed and EMBASE databases. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS), disease-free survival, event-free survival, progression-free survival and treatment-free survival were extracted, if available. Pooled HRs and 95% CIs were used to study any correlation between miR-155 and survival.Results11 studies from 10 articles containing 1718 leukemia patients were included. Data showed that the pooled HR for OS was 1.67 (95% CI: 1.44-1.95, P < 0.01). Subgroup analyses for OS showed that the pooled HRs and their 95% CIs were 1.68, 1.41-2.00 (P < 0.01) and 1.73, 1.25-2.41 (P < 0.01) for acute myeloid leukemia and chronic lymphoblastic leukemia, respectively. Furthermore, there was no significant heterogeneity or publication bias among the enrolled datasets.ConclusionWe conclude that high miR-155 expression was associated with shorter OS for leukemia patients, and that miR-155 might be a promising prognostic biomarker for this patient population.Copyright © 2018 Elsevier B.V. All rights reserved.

13 keywords...

hide…